Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02826486 |
Recruitment Status :
Completed
First Posted : July 11, 2016
Last Update Posted : January 4, 2023
|
Sponsor:
BioLineRx, Ltd.
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
BioLineRx, Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | September 6, 2022 |
Actual Study Completion Date : | September 6, 2022 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):